Nuvectis Pharma (NVCT) Competitors $6.41 -1.06 (-14.19%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends NVCT vs. EXAI, NUVB, TNGX, CRMD, NGNE, QTTB, AVXL, CRVS, LRMR, and ALMSShould you be buying Nuvectis Pharma stock or one of its competitors? The main competitors of Nuvectis Pharma include Exscientia (EXAI), Nuvation Bio (NUVB), Tango Therapeutics (TNGX), CorMedix (CRMD), Neurogene (NGNE), Q32 Bio (QTTB), Anavex Life Sciences (AVXL), Corvus Pharmaceuticals (CRVS), Larimar Therapeutics (LRMR), and Alumis (ALMS). These companies are all part of the "pharmaceutical products" industry. Nuvectis Pharma vs. Exscientia Nuvation Bio Tango Therapeutics CorMedix Neurogene Q32 Bio Anavex Life Sciences Corvus Pharmaceuticals Larimar Therapeutics Alumis Nuvectis Pharma (NASDAQ:NVCT) and Exscientia (NASDAQ:EXAI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation. Does the MarketBeat Community believe in NVCT or EXAI? Exscientia received 2 more outperform votes than Nuvectis Pharma when rated by MarketBeat users. However, 90.00% of users gave Nuvectis Pharma an outperform vote while only 37.93% of users gave Exscientia an outperform vote. CompanyUnderperformOutperformNuvectis PharmaOutperform Votes990.00% Underperform Votes110.00%ExscientiaOutperform Votes1137.93% Underperform Votes1862.07% Do analysts recommend NVCT or EXAI? Nuvectis Pharma currently has a consensus target price of $21.00, indicating a potential upside of 227.61%. Exscientia has a consensus target price of $7.00, indicating a potential upside of 42.86%. Given Nuvectis Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Nuvectis Pharma is more favorable than Exscientia.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvectis Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Exscientia 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has preferable valuation & earnings, NVCT or EXAI? Nuvectis Pharma has higher earnings, but lower revenue than Exscientia. Nuvectis Pharma is trading at a lower price-to-earnings ratio than Exscientia, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuvectis PharmaN/AN/A-$22.26M-$1.29-4.97Exscientia$25.60M23.14-$181.56M-$1.30-3.77 Does the media prefer NVCT or EXAI? In the previous week, Nuvectis Pharma had 1 more articles in the media than Exscientia. MarketBeat recorded 1 mentions for Nuvectis Pharma and 0 mentions for Exscientia. Nuvectis Pharma's average media sentiment score of 0.00 equaled Exscientia'saverage media sentiment score. Company Overall Sentiment Nuvectis Pharma Neutral Exscientia Neutral Which has more volatility & risk, NVCT or EXAI? Nuvectis Pharma has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500. Comparatively, Exscientia has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500. Do insiders & institutionals have more ownership in NVCT or EXAI? 96.8% of Nuvectis Pharma shares are held by institutional investors. Comparatively, 41.6% of Exscientia shares are held by institutional investors. 35.8% of Nuvectis Pharma shares are held by insiders. Comparatively, 16.4% of Exscientia shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is NVCT or EXAI more profitable? Nuvectis Pharma has a net margin of 0.00% compared to Exscientia's net margin of -620.99%. Exscientia's return on equity of -37.56% beat Nuvectis Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Nuvectis PharmaN/A -152.26% -106.23% Exscientia -620.99%-37.56%-26.19% SummaryNuvectis Pharma beats Exscientia on 10 of the 16 factors compared between the two stocks. Ad Porter & CompanyThis is treasonIf you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Get Nuvectis Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NVCT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NVCT vs. The Competition Export to ExcelMetricNuvectis PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$119.55M$7.41B$5.48B$8.52BDividend YieldN/A7.92%5.07%4.13%P/E Ratio-4.9712.34128.5016.14Price / SalesN/A400.631,495.8497.42Price / CashN/A47.4339.6734.18Price / Book9.165.604.765.07Net Income-$22.26M$153.56M$119.00M$225.46M7 Day Performance-26.83%0.13%0.79%0.54%1 Month Performance0.47%15.20%5.64%3.75%1 Year Performance-32.24%41.11%36.71%29.48% Nuvectis Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NVCTNuvectis Pharma1.8853 of 5 stars$6.41-14.2%$21.00+227.6%-30.3%$119.55MN/A-4.978High Trading VolumeEXAIExscientia1.4357 of 5 stars$4.86-5.3%$7.00+44.0%-7.5%$587.51M$21.02M-3.74280Positive NewsNUVBNuvation Bio3.8286 of 5 stars$2.22-5.1%$6.40+188.9%+98.3%$583.23MN/A-1.0560Upcoming EarningsTNGXTango Therapeutics2.7852 of 5 stars$5.44-4.9%$15.14+178.6%-37.3%$582.33M$42.51M-4.7790CRMDCorMedix2.7027 of 5 stars$10.06flat$15.20+51.2%+193.8%$580.79M$806,119.00-10.8130Earnings ReportAnalyst ForecastNews CoverageHigh Trading VolumeNGNENeurogene1.8004 of 5 stars$44.01+0.6%$51.00+15.9%N/A$571.87M$925,000.000.0090QTTBQ32 Bio1.9784 of 5 stars$47.23+2.0%$72.33+53.2%N/A$569.59M$-6,651,000.00-2.0539News CoverageAVXLAnavex Life Sciences3.4898 of 5 stars$6.62+15.9%$40.00+504.2%+21.6%$560.33MN/A-13.2440News CoverageHigh Trading VolumeCRVSCorvus Pharmaceuticals1.5954 of 5 stars$8.84+0.5%$10.83+22.5%+671.2%$550.45MN/A-19.6430Upcoming EarningsAnalyst DowngradeShort Interest ↑LRMRLarimar Therapeutics2.8615 of 5 stars$8.23-2.8%$20.43+148.4%+169.7%$539.80MN/A-7.1530Earnings ReportAnalyst ForecastNews CoverageALMSAlumisN/A$11.32+0.8%$27.50+142.9%N/A$534.51MN/A0.00N/AAnalyst ForecastNews Coverage Related Companies and Tools Related Companies EXAI Alternatives NUVB Alternatives TNGX Alternatives CRMD Alternatives NGNE Alternatives QTTB Alternatives AVXL Alternatives CRVS Alternatives LRMR Alternatives ALMS Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NVCT) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvectis Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvectis Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.